Inivata to present results of analytical validation at the AACR Annual Meeting 2016
Inivata, a global clinical cancer genomics company, will present performance data from the analytical validation of its enhanced TAm-SeqTM (eTAm-SeqTM) proprietary platform for broad molecular profiling, at the American Association for Cancer Research (AACR) Annual Meeting 2016 taking place April 16-20 in New Orleans.
Inivata employs the precision of circulating tumor DNA (ctDNA) analysis to improve targeted cancer care. Inivata will present data demonstrating eTAm-SeqTM molecular profiling as a robust and reproducible method exhibiting high sensitivity and specificity for the detection of genomic alterations in ctDNA. eTAm-Seq profiling of clinical samples revealed the detection of mutations at frequencies that may be missed by less sensitive assays. The analytical validation of eTAm-Seq supports its use in prospective clinical studies to demonstrate the clinical validation and utility in using ctDNA analysis for precision medicine applications particularly for patients where tumor tissue is limited or unavailable.
Details of the poster presentation are as follows:
Poster Session: Genomic Technologies and Analyses
Title: Analytical performance and validation of an enhanced TAm-Seq circulating tumor DNA sequencing assay
Date and Time: Tuesday, April 19, 1:00 – 5:00 PM
Abstract Number: 3639
Location: Section 7
Poster Board Number: 9
Presenter: Davina Gale, co-founder and Head of Molecular Diagnostics, Inivata
Co-authors include scientists and clinicians from Inivata Ltd. and Institut Gustave Roussy.
The poster will be uploaded to the Conference Presentation section of Inivata’s corporate website upon completion of the session to abide by the conference’s embargo policy.
Nitzan Rosenfeld, Inivata CSO, said: “Inivata is pleased to present the results of analytical validation of our enhanced TAm-Seq assay. I am immensely proud of our team, and delighted that we have achieved this excellent performance for our assay, placing Inivata at the front line of sensitivity for liquid biopsies. Having completed our validation to strict quality standards means that our assay is now fit for clinical use. Our ongoing collaborations have shown promising results so far, demonstrating how our test could impact targeted cancer care. Studies we are now undertaking will help establish the clinical utility of this approach and the benefit of Inivata’s liquid biopsies.”
Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse. Inivata’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Its lead product, InVisionFirst®-Lung is commercially available and offers best-in-class sensitivity and turnaround, providing molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata has also launched the personalized RaDaR™ assay – allowing the highly sensitive detection of residual disease and recurrence. Inivata is partnering with pharmaceutical, biotechnology companies and commercial partners in a range of early and late stage cancer development programs. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.